Xarelto was approved by the FDA in November, 2011. Xarelto (Rivaroxaban) is marketed by Bayer. Xarelto is intended to reduce the risk of strokes and blood clots in people with atrial fibrillation. Xarelto is in a class of drugs known as ‘blood thinners.” Xarelto is intended to prevent blood clots from forming by inhibiting the effects of thrombin, which is responsible for clotting. Bayer markets Xarelto as easier to dose, requiring less monitoring, and more effective at preventing clots compared to the other drug in its class, Warfarin (Coumadin).
Xarelto may cause bleeding, which cannot be stopped with vitamin K, unlike Warfarin. With no antidote, Xarelto bleeding may be fatal.
Xarelto and German Authorities Reviewing
It’s reported that German authorities are currently closely scruitinizing reports of Xarelto bleeding deaths. Co-developers Bayer and Johnson and Johnson are working to find an antidote. We believe until an antidote is found, Xarelto remains a very dangerous drug. If an antidote is ever found and we believe Xarelto must contain a black box warning to avoid a public health crisis.
Were you Injured by Xarelto?
The Levensten Law Firm is investigating the legal rights of individuals who suffered serious bleeding events while taking Xarelto